Loading…
Akebia Therapeutics, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in AKBA.
▼ -68.8% over 5Y.
today you would have $311.18▼ -68.9%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 12 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $1.61 | $1.90 | $1.24 | $0.58 | $2.26 | $2.80 | $6.32 | $5.53 | $14.87 | $10.41 | $12.92 | $11.64 | |
| P/S | 2.2x | 1.8x | 2.8x | 1.3x | 0.4x | 1.9x | 1.5x | 2.4x | 3.1x |
Seven formulas applied to what the company reported. None of them predicts a price — each answers what the stock would be worth if its assumption held. The assumption is printed next to every number, because it is the assumption that produces the result.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Cash flow growing 5.0% a year for 10 years, discounted at 10%, then 2.5% forever.
Sector median of 13.3x operating profit, less net debt. Sees the business before its financing, so debt does not distort the comparison. Banks have no EBITDA — interest is their revenue, not a cost.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ELDNEledon Pharmaceuticals, Inc. | $3.20 | — | 3.6x | — | -110.71% | $260.04M |
| NAGENiagen Bioscience, Inc. | $3.29 | 17.3x | 3.2x | — | 21.80% | $260.32M |
| CAMPCamp4 Therapeutics Corp | $4.15 | — | — | — | -545.85% | $260.43M |
| STROSutro Biopharma Inc | $15.73 |
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries; Vafseo License and Collaboration Agreements; CSL Vifor Agreements; Averoa License Agreement; License Agreement with Panion & BF Biotech, Inc.; Cyclerion Therapeutics License Agreement; and Q32 Asset Purchase Agreement. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Company description provided by Yahoo Finance.
| 4.0x |
| 263.3x |
| — |
| — |
| P/B | 4.6x | 13.2x | — | — | 20.3x | 5.5x | 1.8x | 2.1x | 1.0x | 5.9x | 5.9x | 3.7x | 2.3x |
| EPS | -$0.02 | -$0.33 | -$0.28 | -$0.52 | -$1.70 | -$2.78 | -$2.36 | -$2.47 | -$1.69 | -$3.60 | -$2.29 | -$8.04 |
| Profit margin | -56.23% | -2.26% | -43.33% | -26.68% | -32.22% | -133.25% | -130.61% | -83.48% | -69.12% | -40.65% | -8843.45% | — | — |
| ROE | -65.64% | -16.39% | — | — | -1801.64% | -381.07% | -157.49% | -71.18% | -22.58% | -60.10% | -199.28% | -46.35% | -35.58% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Not the average of the seven numbers above. Four of the seven start from the same earnings per share — Graham, Lynch, sector multiples and its own history — so averaging all seven would let one input count four times and drown out the others. Instead each family produces one number, and the fair price is the average of the families that answered. A family with two working formulas contributes their average, not two votes.
2 methods answered, across 2 families.
Every formula reads the same reported statements and they can be wrong together. The margin is room for that.
+242.8% from the average.
These are models, not forecasts, and not investment advice. Change one assumption and the number changes with it — that is a property of valuation, not a defect of this page.
| — |
| — |
| — |
| — |
| $260.82M |
| INFUInfuSystem Holdings, Inc | $13.11 | 32.8x | 4.4x | — | 15.03% | $261.11M |
| ZNTLZentalis Pharmaceuticals, Inc. | $2.70 | — | 1.3x | — | -66.75% | $255.61M |